{
    "title": "Novartis, helped by cost cuts, raises full-year outlook",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12010169/Novartis-lifts-year-earnings-higher-prescriptions.html",
    "date": "2023-04-25",
    "keywords": [
        "drug",
        "cancer",
        "cost",
        "digit",
        "burger",
        "half",
        "year",
        "group",
        "narasimhan",
        "consensus",
        "sclerosis",
        "kisqali",
        "novartis",
        "eye",
        "month",
        "ceo",
        "outlook",
        "trial",
        "success",
        "progress",
        "output",
        "prostate",
        "drugmaker",
        "statement",
        "division",
        "operating",
        "income",
        "percentage",
        "increase",
        "addition",
        "vas",
        "analyst",
        "revenue",
        "psoriasis",
        "cosentyx",
        "injection",
        "breast",
        "treatment",
        "growth",
        "gmt",
        "stock",
        "record",
        "high",
        "safety",
        "beovu",
        "jp",
        "production",
        "rampup",
        "pluvicto",
        "approval",
        "facility",
        "jersey",
        "risk",
        "recurrence",
        "stage",
        "win",
        "investor",
        "pressure",
        "development",
        "drop",
        "disease",
        "gilenya",
        "management",
        "sandoz",
        "spinoff",
        "track",
        "company",
        "capital",
        "day",
        "june",
        "york",
        "business",
        "reporting",
        "rachel",
        "jason",
        "janowski"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}